161 related articles for article (PubMed ID: 20596091)
1. A fully replication-competent adenovirus vector with enhanced oncolytic properties.
Toth K; Kuppuswamy M; Shashkova EV; Spencer JF; Wold WS
Cancer Gene Ther; 2010 Nov; 17(11):761-70. PubMed ID: 20596091
[TBL] [Abstract][Full Text] [Related]
2. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
Dhar D; Spencer JF; Toth K; Wold WS
J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
[TBL] [Abstract][Full Text] [Related]
3. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Toth K; Tarakanova V; Doronin K; Ward P; Kuppuswamy M; Locke JE; Dawson JE; Kim HJ; Wold WS
Cancer Gene Ther; 2003 Mar; 10(3):193-200. PubMed ID: 12637940
[TBL] [Abstract][Full Text] [Related]
4. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
[TBL] [Abstract][Full Text] [Related]
5. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
[TBL] [Abstract][Full Text] [Related]
6. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.
Doronin K; Toth K; Kuppuswamy M; Ward P; Tollefson AE; Wold WS
J Virol; 2000 Jul; 74(13):6147-55. PubMed ID: 10846098
[TBL] [Abstract][Full Text] [Related]
8. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
Spencer JF; Sagartz JE; Wold WS; Toth K
Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
11. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.
Cheng PH; Rao XM; Duan X; Li XF; Egger ME; McMasters KM; Zhou HS
J Mol Med (Berl); 2015 Feb; 93(2):211-23. PubMed ID: 25376708
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
13. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
14. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
16. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
17. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.
Young BA; Spencer JF; Ying B; Tollefson AE; Toth K; Wold WS
Cancer Gene Ther; 2013 Sep; 20(9):521-30. PubMed ID: 23928731
[TBL] [Abstract][Full Text] [Related]
18. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
Dhar D; Toth K; Wold WS
Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
Doronin K; Kuppuswamy M; Toth K; Tollefson AE; Krajcsi P; Krougliak V; Wold WS
J Virol; 2001 Apr; 75(7):3314-24. PubMed ID: 11238857
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]